These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 9611878)

  • 1. [Penetration and intracellular activity of fluoroquinolones].
    Pascual A; García I
    Enferm Infecc Microbiol Clin; 1998 Mar; 16(3):138-43. PubMed ID: 9611878
    [No Abstract]   [Full Text] [Related]  

  • 2. [Penetration of antimicrobial agents into phagocytic cells. Does this determine their therapeutic efficiency?].
    Pascual A
    Enferm Infecc Microbiol Clin; 1989; 7(7):345-7. PubMed ID: 2490458
    [No Abstract]   [Full Text] [Related]  

  • 3. Intracellular penetration and bactericidal activity of the novel des-fluoro(6) quinolone, BMS-284756.
    Kolek B; Warr G; Bonner D; Fung-Tomc J
    J Antimicrob Chemother; 2001 Sep; 48(3):445-6. PubMed ID: 11533015
    [No Abstract]   [Full Text] [Related]  

  • 4. Uptake, transport, delivery, and intracellular activity of antimicrobial agents.
    Mandell GL
    Pharmacotherapy; 2005 Dec; 25(12 Pt 2):130S-133S. PubMed ID: 16305282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Challenges in pharmacodynamic studies of antimicrobial resistance.
    Rapp RP; Campion JJ
    Ann Pharmacother; 2003 Sep; 37(9):1329-30. PubMed ID: 12921518
    [No Abstract]   [Full Text] [Related]  

  • 6. Aqueous and vitreous penetration of topically applied ciprofloxacin and ofloxacin.
    Taustine LR
    J Cataract Refract Surg; 2004 Jan; 30(1):6. PubMed ID: 14967251
    [No Abstract]   [Full Text] [Related]  

  • 7. Cellular uptake and intraphagocytic activity of the new fluoroquinolone AF 3013 against Klebsiella pneumoniae.
    Tullio V; Cuffini AM; Bonino A; Ianni Palarchio A; Rossi V; Carlone NA
    Drugs Exp Clin Res; 1999; 25(1):1-11. PubMed ID: 10337499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Fluoroquinolones--a current review].
    Christ W; Kemmler H
    Med Monatsschr Pharm; 2001 Jul; 24(7):215-25. PubMed ID: 11486553
    [No Abstract]   [Full Text] [Related]  

  • 9. [Impact of fluoroquinolone use on multidrug-resistant bacteria emergence].
    Nseir S; Ader F; Marquette CH; Durocher A
    Pathol Biol (Paris); 2005; 53(8-9):470-5. PubMed ID: 16176863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical pharmacology of the fluoroquinolones: studies in human dynamic/kinetic models.
    Schentag JJ
    Clin Infect Dis; 2000 Aug; 31 Suppl 2():S40-4. PubMed ID: 10984327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibiotic therapy--rationale and evidence for optimal drug concentrations in prostatic and seminal fluid and in prostatic tissue.
    Naber KG; Sörgel F
    Andrologia; 2003 Oct; 35(5):331-5. PubMed ID: 14535866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pharmacokinetic interaction of fluoroquinolones and other drugs].
    Iakovlev VP
    Antibiot Khimioter; 1998; 43(7):36-44. PubMed ID: 9727166
    [No Abstract]   [Full Text] [Related]  

  • 13. Uptake of antimicrobial agents by phagocytic cells.
    Easmon CS
    Chemioterapia; 1987 Jun; 6(2 Suppl):231-2. PubMed ID: 3509394
    [No Abstract]   [Full Text] [Related]  

  • 14. Levofloxacin, a second-generation fluoroquinolone.
    North DS; Fish DN; Redington JJ
    Pharmacotherapy; 1998; 18(5):915-35. PubMed ID: 9758306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interactions of antibiotics with phagocytes in vitro.
    Carlone NA; Cuffini AM; Tullio V; Cavallo G
    J Chemother; 1991 Jan; 3 Suppl 1():98-104. PubMed ID: 12041799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activity of lomefloxacin, a new difluorinated quinolone, against urinary bacterial isolates: comparison with enoxacin and ofloxacin.
    Azadian BS; Talboys CA; Roberts AP
    J Chemother; 1989 Jul; 1(4 Suppl):176-7. PubMed ID: 16312357
    [No Abstract]   [Full Text] [Related]  

  • 17. Mechanisms of action and resistance of older and newer fluoroquinolones.
    Hooper DC
    Clin Infect Dis; 2000 Aug; 31 Suppl 2():S24-8. PubMed ID: 10984324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical implications of pharmacokinetics and pharmacodynamics of fluoroquinolones.
    Wispelwey B
    Clin Infect Dis; 2005 Jul; 41 Suppl 2():S127-35. PubMed ID: 15942879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluoroquinolone AUIC break points and the link to bacterial killing rates: in vitro models.
    Zhanel GG; Noreddin AM
    Ann Pharmacother; 2003 Sep; 37(9):1331-4. PubMed ID: 12921519
    [No Abstract]   [Full Text] [Related]  

  • 20. In vitro evaluation of lomefloxacin (NY-198 or SC-47111), a new difluoro-quinolone.
    Jones RN
    J Chemother; 1989 Jul; 1(4 Suppl):165-7. PubMed ID: 16312353
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.